DXCM DEXCOM INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1093557 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.0%
TTM net income YoY37.5%
TTM EPS YoY41.1%
Revenue 3-yr CAGR14.5%
Net income 3-yr CAGR38.0%
Margins
Gross margin63.4%
Operating margin24.0%
Net margin19.4%
FCF margin21.5%
EBITDA margin29.4%
Returns
ROE37.7%
ROA14.4%
ROIC (approx.)78.0%
Asset turnover0.74x
Leverage & solvency
Liabilities / assets59.4%
Debt / equity0.00x
Current ratio1.74x
Interest coverage91.33x
Cash quality & payout
Operating cash flow / net income1.43x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue6.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.66B | $4.03B |
| Cost of revenue | $1.86B | $1.59B |
| Gross profit | $2.80B | $2.44B |
| R&D expense | $599.10M | $552.40M |
| SG&A expense | $1.29B | $1.29B |
| Operating income | $911.80M | $600.00M |
| Interest expense | $18.30M | $19.00M |
| Pretax income | $1.09B | $709.00M |
| Income tax | $252.10M | $132.80M |
| Net income | $836.30M | $576.20M |
| EBITDA | $1.16B | $817.70M |
| EPS (basic) | 2.14 | 1.46 |
| EPS (diluted) | 2.09 | 1.42 |
| Weighted avg. shares (diluted) | 405.50M | 412.70M |
| Balance sheet | ||
| Cash & equivalents | $917.70M | $607.30M |
| Short-term investments | — | $1.73B |
| Receivables | $1.22B | $1.01B |
| Inventory | $629.10M | $542.60M |
| Current assets | $4.03B | $4.30B |
| PP&E, net | $1.56B | $1.34B |
| Goodwill | $24.20M | $22.80M |
| Intangibles | $70.80M | $103.40M |
| Total assets | $6.34B | $6.48B |
| Current liabilities | $2.14B | $2.93B |
| Total liabilities | $3.59B | $4.38B |
| Shareholders' equity | $2.75B | $2.10B |
| Shares outstanding | 384.80M | 390.70M |
| Cash flow statement | ||
| Operating cash flow | $1.44B | $989.50M |
| Capital expenditure | $363.50M | $358.80M |
| Free cash flow | $1.08B | $630.70M |
| Investing cash flow | $536.00M | -$207.50M |
| Financing cash flow | -$1.69B | -$734.80M |
| Depreciation & amortization | $251.80M | $217.70M |
| Stock-based compensation | $159.60M | $170.40M |
| Share buybacks | $500.00M | $750.00M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.